Comparison of therapeutic effects of wrist-ankle acupuncture, compound diclofenac sodium injection, and morphine hydrochloride injection on renal colic

注册号:

Registration number:

ITMCTR2100004450

最近更新日期:

Date of Last Refreshed on:

2020-11-05

注册时间:

Date of Registration:

2020-11-05

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

腕踝针、复方双氯芬酸钠注射液、盐酸吗啡注射液治疗肾绞痛疗效比较

Public title:

Comparison of therapeutic effects of wrist-ankle acupuncture, compound diclofenac sodium injection, and morphine hydrochloride injection on renal colic

注册题目简写:

English Acronym:

研究课题的正式科学名称:

腕踝针、复方双氯芬酸钠注射液、盐酸吗啡注射液治疗肾绞痛疗效比较

Scientific title:

Comparison of therapeutic effects of wrist-ankle acupuncture, compound diclofenac sodium injection, and morphine hydrochloride injection on renal colic

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000039677 ; ChiMCTR2100004450

申请注册联系人:

梁斯扬

研究负责人:

陈金兰

Applicant:

Liang Siyang

Study leader:

Chen Jinlan

申请注册联系人电话:

Applicant telephone:

+86 18825199246

研究负责人电话:

Study leader's telephone:

+86 13610266623

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

591468420@qq.com

研究负责人电子邮件:

Study leader's E-mail:

lailan@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广东省广州市黄埔区港湾路621号

研究负责人通讯地址:

广东省广州市黄埔区港湾路621号

Applicant address:

621 Gangwan Road, Huangpu District, Guangzhou, Guangdong

Study leader's address:

621 Gangwan Road, Huangpu District, Guangzhou, Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州医科大学附属第五医院

Applicant's institution:

The Fifth affiliated Hospital of Guangzhou Medical University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

GYWY-L2020-38

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

广州医科大学附属第五医院伦理委员会

Name of the ethic committee:

Ethics Committee of the Fifth Affiliated Hospital of Guangzhou Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2020/12/3 0:00:00

伦理委员会联系人:

王小宝

Contact Name of the ethic committee:

WangXiaobao

伦理委员会联系地址:

广东省广州市黄埔区港湾路621号

Contact Address of the ethic committee:

621 Gangwan Road, Huangpu District, Guangzhou, Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20-85959127

伦理委员会联系人邮箱:

Contact email of the ethic committee:

gywyllwyh@126.com

研究实施负责(组长)单位:

广州医科大学附属第五医院

Primary sponsor:

The Fifth affiliated Hospital of Guangzhou Medical University

研究实施负责(组长)单位地址:

广东省广州市黄埔区港湾路621号

Primary sponsor's address:

621 Gangwan Road, Huangpu District, Guangzhou, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州医科大学附属第五医院

具体地址:

黄埔区港湾路621号

Institution
hospital:

The Fifth affiliated Hospital of Guangzhou Medical University

Address:

621 Gangwan Road, Huangpu District

经费或物资来源:

广州医科大学临床重点专科项目

Source(s) of funding:

Clinical key specialist Project of Guangzhou Medical University

研究疾病:

肾绞痛

研究疾病代码:

Target disease:

Renal colic

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

1.比较腕踝针、复方双氯芬酸钠注射液、盐酸吗啡注射液治疗急性肾绞痛的镇痛效果; 2.镇痛后30分钟的疼痛评分平均值、疼痛评分下降≥3的受试者比例、需要拯救镇痛的受试者比例、镇痛后60分钟疼痛评分>2的受试者比例、急性治疗期间发生不良事件的受试者比例。

Objectives of Study:

1. To compare the analgesic effects of wrist-ankle acupuncture, compound diclofenac sodium injection and morphine hydrochloride injection on acute renal colic; 2. The average pain score at 30 minutes after analgesia, the proportion of subjects whose pain score decreased >= 3, the proportion of subjects who needed rescue analgesia, the proportion of subjects whose pain score > 2 60 minutes after analgesia, and the proportion of subjects with adverse events during acute treatment.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)年龄18-65岁,性别不限; (2)经超声、X线或CT 检查证实为肾盂、输尿管结石导致突发性腰腹部剧烈疼痛、尿痛、排尿困难等症状的急性肾绞痛患者; (3)生命体征平稳,无高热、寒战等症状; (4)双侧手腕、脚踝关节无畸形,皮肤无皮损; (5)自愿参加本临床试验,并签署书面知情同意书。

Inclusion criteria

(1) 18-65 years old, gender is not limited; (2) Acute renal entanglement with renal pelvis and ureteral stones confirmed by ultrasound, X-ray or CT examination, causing sudden severe waist and abdomen pain, dysuria, dysuria, etc. Pain patients; (3) stable vital signs, no symptoms of high fever, chills, etc.; (4) bilateral wrist and ankle joints without deformities, and no skin lesions; (5) voluntarily participate in this clinical trial and sign a written informed consent.

排除标准:

(1)存在严重心、肝、肾等脏器病变或不能依从者; (2)不能控制的全身出血性疾病; (3)出现高热、寒战症状需要马上手术干预的患者; (4)妊娠、严重体虚者; (5)双侧手腕、脚踝关节存在畸形,皮肤存在皮损; (6)非甾体抗炎药(NSAID)或对吗啡超敏反应者; (7)由尿石症以外的原因导致的肾绞痛患者; (8)在本机构治疗前6小时内使用过其他止痛药的患者; (9)研究者评估患者情况认为不适合参加本试验者。

Exclusion criteria:

(1) Patients with severe heart, liver, kidney and other organ diseases or who cannot comply; (2) Uncontrollable systemic bleeding diseases; (3) Patients with high fever and chills that require immediate surgical intervention; (4) Pregnancy, Severe physical weakness; (5) Bilateral wrist and ankle joint deformities, skin lesions; (6) Non-steroidal anti-inflammatory drugs (NSAID) or hypersensitivity to morphine; (7) Other than urolithiasis Patients with renal colic caused by the causes of the disease; (8) Patients who have used other painkillers within 6 hours before treatment at this institution; (9) The investigator assessed the patients condition and deemed it unsuitable to participate in this trial.

研究实施时间:

Study execute time:

From 2020-12-01

To      2022-09-30

征募观察对象时间:

Recruiting time:

From 2020-12-01

To      2022-06-01

干预措施:

Interventions:

组别:

复方双氯芬酸钠注射液组

样本量:

75

Group:

Compound diclofenac sodium injection group

Sample size:

干预措施:

复方双氯芬酸钠注射液

干预措施代码:

02

Intervention:

Compound diclofenac sodium injection

Intervention code:

组别:

腕踝针组

样本量:

75

Group:

wrist-ankle acupuncture group

Sample size:

干预措施:

腕踝针治疗

干预措施代码:

01

Intervention:

wrist-ankle acupuncture

Intervention code:

组别:

盐酸吗啡注射液组

样本量:

75

Group:

Morphine hydrochloride injection group

Sample size:

干预措施:

盐酸吗啡注射液

干预措施代码:

03

Intervention:

Morphine hydrochloride injection

Intervention code:

样本总量 Total sample size : 225

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

云南

市(区县):

大理

Country:

China

Province:

Yunnan

City:

Dali

单位(医院):

大理市祥云县人民医院

单位级别:

二级

Institution/hospital:

Xiangyun County People's Hospital of Dali

Level of the institution:

Secondary

国家:

中国

省(直辖市):

广东

市(区县):

江门

Country:

China

Province:

Guangdong

City:

Jiangmen

单位(医院):

江门市人民医院

单位级别:

三级

Institution/hospital:

Jiangmen People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

云南

市(区县):

保山

Country:

China

Province:

Yunnan

City:

Baoshan

单位(医院):

保山市第二人民医院

单位级别:

二级

Institution/hospital:

Baoshan Second People's Hospital

Level of the institution:

Secondary

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州医科大学附属第五医院

单位级别:

三级

Institution/hospital:

The Fifth affiliated Hospital of Guangzhou Medical University

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

广东

市(区县):

高州

Country:

China

Province:

Guangdong

City:

Gaozhou

单位(医院):

高州市人民医院

单位级别:

三级

Institution/hospital:

Gaozhou People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

云南

市(区县):

昆明

Country:

China

Province:

Yunnan

City:

Kunming

单位(医院):

昆明医科大学第二附属医院

单位级别:

三级

Institution/hospital:

The Second Affiliated Hospital of Kunming Medical University

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

心率

指标类型:

主要指标

Outcome:

heart rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体温

指标类型:

主要指标

Outcome:

temperature

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

VAS 评分

指标类型:

主要指标

Outcome:

VAS score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心电图

指标类型:

主要指标

Outcome:

ECG

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量指数评分

指标类型:

主要指标

Outcome:

Quality of life index score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿常规

指标类型:

主要指标

Outcome:

Urine routine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

主要指标

Outcome:

Blood pressure

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗后伴随症状

指标类型:

主要指标

Outcome:

Concomitant symptoms after treatment

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腹部影像检查

指标类型:

主要指标

Outcome:

Abdominal imaging examination

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

主要指标

Outcome:

Blood routine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗前伴随症状

指标类型:

主要指标

Outcome:

Concomitant symptoms before treatment

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机序列由研究员采用电脑随机数字生成法产生。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random sequences are generated by researchers using computer random number generation.

盲法:

开放

Blinding:

open-label

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2023-03-30 请说明共享原始数据的方式

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

March 30th, 2023

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Use CRF

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above